Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Research & Development: 2009-2024

Historic Research & Development for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $21.4 million.

  • Ligand Pharmaceuticals' Research & Development rose 270.38% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.1 million, marking a year-over-year increase of 265.07%. This contributed to the annual value of $21.4 million for FY2024, which is 12.68% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' Research & Development stood at $21.4 million, which was down 12.68% from $24.5 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Research & Development high stood at $40.5 million for FY2020, and its period low was $21.4 million during FY2024.
  • Its 3-year average for Research & Development is $27.3 million, with a median of $24.5 million in 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Research & Development increased by 12.39% in 2022 and then slumped by 32.00% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Research & Development (Yearly) stood at $40.5 million in 2020, then dropped by 20.73% to $32.1 million in 2021, then climbed by 12.39% to $36.1 million in 2022, then slumped by 32.00% to $24.5 million in 2023, then dropped by 12.68% to $21.4 million in 2024.